Lineage Cell Therapeutics... (LCTX)
Lineage Cell Therapeutics Statistics
Share Statistics
Lineage Cell Therapeutics has 228.36M shares outstanding. The number of shares has increased by 20.94% in one year.
| Shares Outstanding | 228.36M |
| Shares Change (YoY) | 20.94% |
| Shares Change (QoQ) | 3.6% |
| Owned by Institutions (%) | 56.7% |
| Shares Floating | 227.36M |
| Failed to Deliver (FTD) Shares | 213.54K |
| FTD / Avg. Volume | 13.75% |
Short Selling Information
The latest short interest is 26.64M, so 11.67% of the outstanding shares have been sold short.
| Short Interest | 26.64M |
| Short % of Shares Out | 11.67% |
| Short % of Float | 18.49% |
| Short Ratio (days to cover) | 12.57 |
Valuation Ratios
The PE ratio is -5.41 and the forward PE ratio is -6.92. Lineage Cell Therapeutics's PEG ratio is 0.22.
| PE Ratio | -5.41 |
| Forward PE | -6.92 |
| PS Ratio | 10.59 |
| Forward PS | 2.3 |
| PB Ratio | 1.31 |
| P/FCF Ratio | -4.36 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lineage Cell Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.65, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.65 |
| Quick Ratio | 3.65 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.11 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $135.7K |
| Profits Per Employee | $-265.84K |
| Employee Count | 70 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 27K |
| Effective Tax Rate | -0.15% |
Stock Price Statistics
The stock price has increased by -65% in the last 52 weeks. The beta is 1.33, so Lineage Cell Therapeutics's price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -65% |
| 50-Day Moving Average | 0.54 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 39.49 |
| Average Volume (20 Days) | 1.55M |
Income Statement
In the last 12 months, Lineage Cell Therapeutics had revenue of 9.5M and earned -18.61M in profits. Earnings per share was -0.09.
| Revenue | 9.5M |
| Gross Profit | 9.16M |
| Operating Income | -21.48M |
| Net Income | -18.61M |
| EBITDA | -21.48M |
| EBIT | -21.48M |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 45.79M in cash and 2.51M in debt, giving a net cash position of 43.27M.
| Cash & Cash Equivalents | 45.79M |
| Total Debt | 2.51M |
| Net Cash | 43.27M |
| Retained Earnings | -403.46M |
| Total Assets | 113.22M |
| Working Capital | 37.02M |
Cash Flow
In the last 12 months, operating cash flow was -23.09M and capital expenditures 0, giving a free cash flow of -23.09M.
| Operating Cash Flow | -23.09M |
| Capital Expenditures | 0 |
| Free Cash Flow | -23.09M |
| FCF Per Share | -0.12 |
Margins
Gross margin is 96.48%, with operating and profit margins of -226.11% and -195.9%.
| Gross Margin | 96.48% |
| Operating Margin | -226.11% |
| Pretax Margin | -195.62% |
| Profit Margin | -195.9% |
| EBITDA Margin | -226.11% |
| EBIT Margin | -226.11% |
| FCF Margin | -243.1% |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LCTX is $3, which is 614.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 614.3% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Oct 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | -3.46 |
| Piotroski F-Score | 3 |